Equity Overview
Price & Market Data
Price: $16.66
Daily Change: -$1.12 / 6.72%
Daily Range: $16.11 - $18.53
Market Cap: $729,661,376
Daily Volume: 289,768
Performance Metrics
1 Week: 5.84%
1 Month: 47.96%
3 Months: 98.10%
6 Months: 3.41%
1 Year: 3.41%
YTD: 4.45%
Company Details
Employees: 125
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.